Company profile: Ocera Therapeutics
1.1 - Company Overview
Company description
- Provider of novel therapeutics in development for patients with acute and chronic liver disease, as a clinical-stage biopharmaceutical company focused on development and commercialization in an area of high unmet medical need; HE clinical development includes a recently completed Phase 2b trial, STOP-HE, which evaluated safety.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ocera Therapeutics
OxThera
HQ: Sweden
Website
- Description: Provider of biopharmaceutical treatments for primary and secondary hyperoxaluria, developing late-stage oral therapies: Oxabact, which promotes secretion of oxalate from plasma into the gut for degradation in patients with Primary Hyperoxaluria; and Oxazyme, a recombinant oxalate decarboxylase that degrades dietary oxalate in the gut for Secondary Hyperoxaluria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OxThera company profile →
Carmot Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery and development for inflammatory, metabolic, and neurological diseases, leveraging its patented Chemotype Evolution platform to accelerate discovery of disease‑modifying therapies. Pipeline includes CT‑388 and CT‑868 (dual GLP‑1/GIP agonists), CT‑996 (oral GLP‑1 agonist) for obesity and type 1 diabetes, and CT‑PYY for Prader‑Willi syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carmot Therapeutics company profile →
Metacrine
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on building an innovative pipeline of best-in-class drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Metacrine company profile →
PhaseBio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical drug development targeting cardiovascular, endocrine, and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhaseBio company profile →
CymaBay
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development and commercialization of proprietary new medicines for important human diseases, including Seladelpar—an investigational treatment for primary biliary cholangitis—and PBC-focused clinical trials such as IDEAL, AFFIRM, PBC with Hepatic Impairment, ASSURE, and RESPONSE.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CymaBay company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ocera Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ocera Therapeutics
2.2 - Growth funds investing in similar companies to Ocera Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ocera Therapeutics
4.2 - Public trading comparable groups for Ocera Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →